Welcome to our dedicated page for Ptc Therapeutics SEC filings (Ticker: PTCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PTC Therapeutics, Inc. (PTCT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Delaware corporation listed on the Nasdaq Global Select Market under the symbol PTCT, PTC uses SEC reports to communicate material events, financial results and key agreements related to its rare disease biopharmaceutical business.
Among the filings, investors can find Form 8-K current reports detailing quarterly financial results, such as revenue from Sephience (sepiapterin), the Duchenne muscular dystrophy franchise (Translarna and Emflaza), and royalty and collaboration revenue including Evrysdi (risdiplam). 8-K filings also describe significant corporate events, including FDA approvals like the U.S. approval of Sephience for phenylketonuria (PKU), regulatory correspondence such as a Complete Response Letter for vatiquinone in Friedreich’s ataxia, and material agreements like the Rights Satisfaction Agreement with former Censa securityholders related to sepiapterin net sales payments.
Through its periodic reports (such as Forms 10-K and 10-Q, when available), PTC Therapeutics provides more extensive information on its business, risk factors, R&D and SG&A expenses, cash position, royalty and collaboration structures, and the status of programs including Translarna, Emflaza, Sephience, votoplam, vatiquinone, Upstaza/Kebilidi, Tegsedi and Waylivra. These filings also confirm the company’s incorporation in Delaware and its principal executive offices in Warren, New Jersey.
Stock Titan enhances access to PTCT filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand revenue composition, major agreements, regulatory developments and forward-looking statements. Real-time updates from EDGAR mean new 8-Ks, 10-Qs, 10-Ks and other forms appear promptly, while Form 4 insider transaction reports and proxy materials, when filed, can offer additional insight into equity awards, executive compensation and ownership changes.
By using this filings page, investors and researchers can review the official record of how PTC Therapeutics describes its rare disease portfolio, collaborations, financial performance and risks in its own words to U.S. regulators.
An affiliate of PTCT filed a notice of proposed sale under Rule 144 for 2,813 common shares, to be sold through Fidelity Brokerage Services on NASDAQ at an aggregate market value of 194,490.82. Shares outstanding were 80,288,305 as of the filing. The seller acquired these shares on 02/17/2026 via an option granted on 02/15/2024, paid in cash. Over the prior three months, the same holder reported several additional common share sales, including 4,879 shares on 01/07/2026 for gross proceeds of 377,839.55 and 4,033 shares on 01/08/2026 for 308,761.28.
Janus Henderson Group plc reported beneficial ownership of 4,851,332 shares of PTC Therapeutics, Inc. common stock, representing 6.0% of the class as of 12/31/2025. All voting and dispositive power over these shares is shared, with no sole authority reported.
The position arises through multiple Janus Henderson asset management subsidiaries that exercise investment and/or voting discretion for various managed portfolios. Those managed portfolios receive all dividends and sale proceeds from the shares, and no single portfolio holds more than five percent of PTC Therapeutics’ common stock. Janus Henderson certifies the holdings are passive and not for influencing control.
The Toronto-Dominion Bank has reported a significant ownership stake in PTC Therapeutics, Inc. The bank beneficially owns 4,138,215 shares of PTC Therapeutics common stock, representing 5.2% of the outstanding class as of 12/31/2025.
TD Bank reports sole power to vote and dispose of all 4,138,215 shares, with no shared voting or dispositive power. The bank states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of PTC Therapeutics.
PTC Therapeutics has withdrawn its New Drug Application resubmission for Translarna (ataluren) as a treatment for nonsense mutation Duchenne muscular dystrophy after U.S. FDA feedback on the review. FDA indicated the data are unlikely to meet its standard of substantial evidence of effectiveness needed for approval.
CEO Matthew B. Klein said the company is disappointed that FDA approval for Translarna in the U.S. “cannot be achieved” despite more than two decades of development work. The update underscores the challenges of securing U.S. approval for this rare disease therapy, even as PTC continues broader work on treatments for genetic disorders.
Wellington Management Group LLP and affiliated entities report a passive ownership position in PTC Therapeutics, Inc. common stock. As of the event date of December 31, 2025, they collectively report beneficial ownership of 3,867,380 shares, representing 4.8% of the outstanding common stock.
The filing shows no sole voting or dispositive power, with 3,316,002 shares subject to shared voting power and 3,867,380 shares subject to shared dispositive power. The shares are owned of record by clients of various Wellington investment advisers, and no single client is known to hold more than five percent of the class.
The reporting groups certify the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of PTC Therapeutics.
State Street Corporation has reported a significant passive stake in PTC Therapeutics, Inc.. As of December 31, 2025, State Street beneficially owned 4,206,126 shares of PTC Therapeutics common stock, representing 5.2% of the outstanding class.
State Street reports no sole voting or dispositive power, with 3,973,329 shares subject to shared voting power and 4,206,126 shares subject to shared dispositive power, held through investment management subsidiaries. It certifies the holdings are in the ordinary course of business and not for the purpose of influencing control of PTC Therapeutics.
PTC Therapeutics senior vice president and chief accounting officer Christine Marie Utter reported an automatic sale of 1,034 shares of common stock on January 8, 2026 at $76.45 per share. The filing explains these shares were sold under an irrevocable "sell to cover" election to satisfy tax withholding obligations tied to the vesting of 2,900 restricted stock units from a January 7, 2022 grant of 11,600 RSUs. After this tax-related sale, she beneficially owned 72,693 shares of PTC Therapeutics common stock.
PTC Therapeutics, Inc. chief business officer Eric Pauwels reported a series of planned stock sales in January 2026. The Form 4 shows multiple open-market sales of PTC Therapeutics common stock on January 8, 9, and 12, 2026, at weighted average prices around the mid‑$70s per share, with transaction prices including $76.42, $76.98, $76.45, $77.41 and $78.70 per share. These transactions were executed under a written Rule 10b5‑1 trading plan adopted on September 15, 2025, meaning they were pre‑scheduled rather than discretionary trades.
One sale of 1,454 shares on January 8, 2026, was automatically executed to cover tax withholding obligations tied to the vesting of 4,200 restricted stock units from a January 7, 2022 grant of 16,800 RSUs. After the reported transactions, Pauwels directly held 80,141 shares of PTC Therapeutics common stock.
PTC Therapeutics, Inc. reported an insider share sale by its chief executive officer Matthew B. Klein. On January 8, 2026, he sold 2,514 shares of common stock at $76.45 per share. After this transaction, he beneficially owned 394,453 shares of PTC Therapeutics common stock in direct ownership.
The filing explains that these shares were automatically sold under an irrevocable “sell to cover” election to satisfy tax withholding obligations tied to the vesting of 5,250 restricted stock units (RSUs) from a January 7, 2022 grant of 21,000 RSUs. This indicates the sale was made to cover taxes due on equity compensation rather than as a discretionary open‑market sale of investment holdings.
PTC Therapeutics executive Golden Lee Scott reported an automatic share sale related to tax withholding. On January 8, 2026, Scott sold 866 shares of PTC Therapeutics common stock at $76.45 per share. After this transaction, Scott beneficially owned 92,428 shares of common stock in direct form.
According to the footnote, the sale was made automatically under an irrevocable "sell to cover" election entered into when the equity awards were granted. The sale was used to satisfy tax withholding obligations tied to the vesting of 3,539 restricted stock units (RSUs) from January 7, 2022 grants that originally totaled 14,155 RSUs. This indicates the transaction was administrative in nature and connected to previously granted equity compensation.